BioInvent International AB (publ) (STO: BINV)

Sweden flag Sweden · Delayed Price · Currency is SEK
35.95
+0.10 (0.28%)
Aug 30, 2024, 5:29 PM CET
116.31%
Market Cap 2.37B
Revenue 52.67M
Net Income -383.48M
Shares Out 65.80M
EPS -5.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 58,439
Open 35.80
Previous Close 35.85
Day's Range 35.50 - 36.55
52-Week Range 14.00 - 45.40
Beta 0.39
Analysts n/a
Price Target n/a
Earnings Date Oct 31, 2024

About BINV

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 111
Stock Exchange Nasdaq Stockholm
Ticker Symbol BINV
Full Company Profile

News

There is no news available yet.